Standard BioTools Inc. Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions
Standard BioTools Inc. (LAB) reported Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions of $357.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions · last filed 2026-03-16
- Standard BioTools Inc. unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2024 was $357.00K, a 158.70% increase from fiscal 2023.
- Standard BioTools Inc. unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2023 was $138.00K, a 91.87% decline from fiscal 2022.
- Standard BioTools Inc. unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2022 was $1.70M, a 135.37% increase from fiscal 2021.
- Standard BioTools Inc. unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2021 was $721.00K, a 400.69% increase from fiscal 2020.
| Period end | Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions 12 month |
|---|---|
| 2024-12-31 | $357.00K 10-K · filed 2026-03-16 |
| 2023-12-31 | $138.00K 10-K · filed 2026-03-16 |
| 2022-12-31 | $1.70M 10-K · filed 2025-03-11 |
| 2021-12-31 | $721.00K 10-K · filed 2023-03-14 |
| 2020-12-31 | $144.00K 10-K · filed 2022-03-08 |
| 2019-12-31 | $20.00K 10-K · filed 2022-03-08 |
| 2018-12-31 | $228.00K 10-K · filed 2021-02-25 |
| 2017-12-31 | $2.08M 10-K · filed 2020-02-27 |
| 2016-12-31 | $1.05M 10-K · filed 2019-03-18 |
| 2015-12-31 | $59.00K 10-K · filed 2018-03-08 |
| 2014-12-31 | $8.00K 10-K · filed 2017-03-03 |
| 2013-12-31 | $547.00K 10-K · filed 2016-02-29 |
| 2010-12-31 | $833.00K 10-K · filed 2013-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |